Literature DB >> 14688314

The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells.

Wei Wang1, Norma S Ostlie, Bianca M Conti-Fine, Monica Milani.   

Abstract

Autoantibodies to the muscle acetylcholine receptor (AChR) cause the symptoms of human and experimental myasthenia gravis (EMG). AChR-specific CD4+ T cells permit development of these diseases, but the role(s) of the Th1 and Th2 subsets is unclear. The STAT4 and STAT6 proteins, which mediate intracellular cytokine signaling, are important for differentiation of Th1 and Th2 cells, respectively. Wild-type (WT) BALB/c mice, which are prone to develop Th2 rather than Th1 responses to Ag, are resistant to EMG. We have examined the role of Th1 and Th2 cells in EMG using STAT4 (STAT4-/-)- or STAT6 (STAT6-/-)-deficient BALB/c mice. After AChR immunization, STAT6-/- mice were susceptible to EMG: they developed more serum anti-AChR Ab, and had more complement-fixing anti-AChR IgG2a and 2b and less IgG1 than WT or STAT4-/- mice. The susceptibility to EMG of STAT6-/- mice is most likely related to the Th1 cell-induced synthesis of anti-AChR Ab, which trigger complement-mediated destruction of the neuromuscular junction. CD4+ T cells of the STAT6-/- mice had proliferative responses to the AChR comparable to those of WT and STAT4-/- mice, and recognized similar AChR epitopes. STAT6-/- mice had abundant AChR-specific Th1 cells, which were nearly absent in WT and STAT4-/- mice. Spleen and lymph nodes from STAT6-/- mice contained cells that secreted IL-4 when cultured with AChR: these are most likely STAT6-independent cells, stimulated in a non-Ag-specific manner by the cytokines secreted by AChR-specific Th1 cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14688314     DOI: 10.4049/jimmunol.172.1.97

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

Review 1.  STAT4: a critical regulator of inflammation in vivo.

Authors:  Mark H Kaplan
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity.

Authors:  Amanda K Huber; Eric M Jacobson; Krystian Jazdzewski; Erlinda S Concepcion; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

3.  C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.

Authors:  Wei Wang; Monica Milani; Norma Ostlie; David Okita; Rajeev K Agarwal; Rachel R Caspi; Rachel Caspi; Bianca M Conti-Fine
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

4.  High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups.

Authors:  Bahram Namjou; Andrea L Sestak; Don L Armstrong; Raphael Zidovetzki; Jennifer A Kelly; Noam Jacob; Voicu Ciobanu; Kenneth M Kaufman; Joshua O Ojwang; Julie Ziegler; Francesco P Quismorio; Andreas Reiff; Barry L Myones; Joel M Guthridge; Swapan K Nath; Gail R Bruner; Ruth Mehrian-Shai; Earl Silverman; Marisa Klein-Gitelman; Deborah McCurdy; Linda Wagner-Weiner; James J Nocton; Chaim Putterman; Sang-Cheol Bae; Yun Jung Kim; Michelle Petri; John D Reveille; Timothy J Vyse; Gary S Gilkeson; Diane L Kamen; Marta E Alarcón-Riquelme; Patrick M Gaffney; Kathy L Moser; Joan T Merrill; R Hal Scofield; Judith A James; Carl D Langefeld; John B Harley; Chaim O Jacob
Journal:  Arthritis Rheum       Date:  2009-04

5.  A Natural Variant of the Signaling Molecule Vav1 Enhances Susceptibility to Myasthenia Gravis and Influences the T Cell Receptor Repertoire.

Authors:  Isabelle Bernard; Antoine Sacquin; Sahar Kassem; Mehdi Benamar; Céline Colacios; Mylène Gador; Corine Pérals; Nicolas Fazilleau; Abdelhadi Saoudi
Journal:  Front Immunol       Date:  2018-10-25       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.